VEGFA and endophthalmitis: Xu et al. recently showed a reduced incidence of endophthalmitis after IVI performed in an outpatient clinic setting (40 cases among 258,357 IVI), without topical antibiotic eyedrops after the injection; this retrospective study considered only anti-VEGF agents (bevacizumab, ranibizumab, and aflibercept), injected using a 30-gauge needle [18].